Healthcare SaaS: 340% Pipeline Growth

The Challenge

A healthcare technology company with strong product-market fit was stuck. Despite having a solution that customers loved once implemented, the sales process was painfully slow. Average sales cycles stretched beyond 9 months, win rates hovered around 15%, and the pipeline wasn't growing fast enough to meet investor expectations.

The leadership team had tried the obvious fixes: more sales reps, better training, refined targeting. Nothing moved the needle significantly.

The Discovery

Our Customer Choice Intelligence analysis revealed the core problem: the company was selling to the wrong people, with the wrong message.

Their sales process targeted IT departments, focusing on technical capabilities and integration features. But the actual purchase decisions were driven by clinical leadership, who cared about patient outcomes and workflow efficiency, topics barely mentioned in sales materials.

Furthermore, the evaluation criteria shifted dramatically between early-stage interest and final decision. Early conversations emphasized features, but closing deals required demonstrating ROI and implementation risk mitigation.

The Transformation

We rebuilt their go-to-market approach around these insights:

Repositioned messaging from technical capabilities to clinical outcomes, with specific metrics around patient care improvements and staff efficiency gains.

Restructured the sales process to engage clinical stakeholders early, not as an afterthought. Created role-specific content and conversation guides.

Developed an ROI model that quantified the business case in terms healthcare executives cared about: reduced readmissions, improved patient satisfaction scores, staff retention.

Built implementation confidence through case studies, reference programs, and a clearer project methodology that addressed the risk concerns driving delays.

The Results

Within two quarters:

• Pipeline growth accelerated to 340% year-over-year
• Average sales cycle compressed from 9+ months to 4.2 months
• Win rates improved 2.8x
• Average deal size increased 23% as larger health systems entered the pipeline

The company exceeded their annual revenue target by Q3 and closed a Series C round at a significantly higher valuation than originally projected.